Valuation: Kenvue Inc.

Capitalization 33.14B 28.31B 26.1B 24.63B 45.77B 3,103B 46.94B 306B 120B 1,482B 124B 122B 5,293B P/E ratio 2026 *
18.4x
P/E ratio 2027 * 16.8x
Enterprise value 40.71B 34.78B 32.07B 30.26B 56.23B 3,812B 57.66B 376B 148B 1,820B 153B 150B 6,503B EV / Sales 2026 *
2.62x
EV / Sales 2027 * 2.52x
Free-Float
99.66%
Yield 2026 *
4.93%
Yield 2027 * 5.05%
1 day+0.78%
1 week+3.92%
Current month+0.84%
1 month-1.84%
3 months+1.55%
6 months+7.65%
Current year+0.78%
1 week 16.76
Extreme 16.76
17.56
1 month 16.64
Extreme 16.64
17.96
Current year 16.56
Extreme 16.555
19.18
1 year 14.02
Extreme 14.02
25.17
3 years 14.02
Extreme 14.02
27.8
5 years 14.02
Extreme 14.02
27.8
10 years 14.02
Extreme 14.02
27.8
Manager TitleAgeSince
Chief Executive Officer 59 14/07/2025
Director of Finance/CFO 57 12/05/2025
Chief Tech/Sci/R&D Officer 57 -
Director TitleAgeSince
Chairman 70 01/05/2023
Director/Board Member 66 04/05/2023
Director/Board Member 58 08/05/2023
Change 5d. change 1-year change 3-years change Capi.($)
+0.84%+3.92%-23.45% - 33.14B
+0.61%+2.34%-14.50%-4.24% 334B
-0.63%+1.85%-19.19%-12.03% 126B
+0.68%+1.59%-11.09%+11.72% 67.38B
-1.30%+2.03%-10.10%-16.13% 58.71B
+0.74%+9.20%+35.87%-70.26% 26.97B
+1.58%+3.07%-35.47%-37.05% 19.13B
+0.90%+1.56%-11.12%-19.18% 18.08B
-1.69%+5.78%-13.38%+10.04% 11.58B
+1.65%+18.90%+489.23% - 10.06B
Average +0.32%+4.12%+38.68%-17.14% 70.49B
Weighted average by Cap. +0.22%+1.93%-6.42%-8.95%

Financials

2026 *2027 *
Net sales 15.55B 13.29B 12.25B 11.56B 21.48B 1,456B 22.03B 143B 56.41B 695B 58.36B 57.12B 2,484B 15.95B 13.62B 12.56B 11.85B 22.03B 1,493B 22.59B 147B 57.85B 713B 59.85B 58.58B 2,547B
Net income 1.82B 1.55B 1.43B 1.35B 2.51B 170B 2.58B 16.78B 6.6B 81.32B 6.82B 6.68B 290B 2B 1.71B 1.57B 1.48B 2.76B 187B 2.83B 18.42B 7.24B 89.28B 7.49B 7.33B 319B
Net Debt 7.57B 6.47B 5.96B 5.63B 10.46B 709B 10.73B 69.86B 27.47B 339B 28.42B 27.82B 1,210B 7.03B 6.01B 5.54B 5.23B 9.71B 658B 9.96B 64.86B 25.5B 314B 26.38B 25.82B 1,123B
Logo Kenvue Inc.
Kenvue Inc. is one of the world leaders in the design, manufacture and marketing of consumer healthcare products. The group offers products for health, beauty, baby care, oral care, skin care and more. Net sales break down by family of products as follows: - self care products (42,3%): for the treatment of coughs, colds, allergies, pain, indigestion, constipation, etc. (brands Zyrtec, Benadryl, Zarbee's, Frenadol, Codral, Reactine, Tylenol, Motrin, Calpol, Nicorette, Imodium, Pepcid, Microlax, Daktarin, etc.); - personal care products (30.3%): primarily oral care, baby care, women's health and wound care products (Listerine, Desitin, Carefree, Stayfree, Band-Aid, Neosporin brands, etc.); - beauty and skin care products (27.4%): hair care products, sun protection products, face and body care products, etc. (Neutrogena, Aveeno, Clean&Clear, Lubriderm, Johnsons, Neostrata, OGX, Rogaine brands, etc.). Product marketing is assured through direct sales, distributors and the Internet. Net sales are distributed geographically as follows: North America (49%), Europe-Middle East-Africa (23%), Asia-Pacific (19.3%) and Latin America (8.7%).
Employees
21,890
Date Price Change Volume
14/04/26 17.40 $ +0.81% 2,445,846
13/04/26 17.26 $ -0.52% 16,081,700
10/04/26 17.35 $ -0.46% 12,786,699
09/04/26 17.43 $ +0.52% 31,031,682
08/04/26 17.34 $ +3.65% 20,367,223
Trader
Investor
Global
Quality
ESG MSCI
A
Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
12
Last Close Price
17.26USD
Average target price
19.75USD
Spread / Average Target
+14.43%

Quarterly revenue - Rate of surprise